Hematologic Malignancies: Polycythemia Vera | Special Reports

September 29, 2016

Heinz Gisslinger, MD, Medical University of Vienna, discusses differences between polycythemia vera (PV) and essential thrombocythemia (ET).

September 28, 2016

Haifa Kathrin Al-Ali, MD, and Carlos Besses, MD, PhD debated the need for new drugs to treat polycythemia vera (PV) and essential thrombocythemia (ET).

September 28, 2016

Since its approval 5 years ago, ruxolitinib (Jakafi) continues to drastically change the treatment landscape and quality of life of patients with myeloproliferative neoplasms (MPNs), including a subset of patients with the bone marrow neoplasm, polycythemia vera (PV).

September 28, 2016

Distinguishing between polycythemia vera (PV) and essential thrombocythemia (ET) is key for the effective treatment of both diseases, said Heinz Gisslinger, MD, of the Medical University of Vienna.

September 27, 2016

In an interview with Targeted Oncology, Srdan Verstovsek, MD, PhD, of the University of Texas MD Anderson Cancer Center, discusses recent developments in polycythemia vera.

September 27, 2016

Follow up at 80 weeks to the open-label phase III RESPONSE trial confirmed the benefit of ruxolitinib over best available therapy (BAT) in the treatment of patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea.

September 27, 2016

Srdan Verstovsek, MD, PhD, Chief, Section for Myeloproliferative Neoplasms at the University of Texas MD Anderson Cancer Center, discusses the most recent developments in diagnosing polycythemia vera.